Citations

Clear

3138 citation(s) found for "Smith, AM".

Surgical Outcomes of Endoscopic Versus Open Resection for Primary Sinonasal Malignancy: A Meta-analysis
Lu, Victor M. , Ravindran, Krishnan , Smith, Timothy R. , Donaldson, Angela M. , Quiñones‐Hinojosa, Alfredo , Mekary, Rania A. , Chaichana, Kaisorn L. , Phan, Kevin H. , Gompel, Jamie J. Van

Mayo Clinic

American Journal of Rhinology & Allergy | June 20, 2019 | Volume: 33 | Issue: 5 | Pages: 608-616

10.1177/1945892419856976 | PMID 31219311 Get It

Background Endoscopic resection (ER) for uncommon sinonasal malignancies (SNMs) has been reported to confer superior surgical outcomes compared to open resection (OR) based on indirect comparisons of limited evidence. Objective The aim of this study was to pool all direct comparative studies in the literature to validate this potential superior association. Methods Systematic searches of 7 electronic databases from their inception to April 2019 were conducted following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. There were 1001 articles identified for screening. Outcomes of interest were pooled as risk ratios (RRs) and mean difference (MD) and analyzed using a random-effects model. Results There were 10 studies included in this meta-analysis, with 900 SNM patients in total where ER and OR were utilized in 399 (44%) and 501 (56%) cases, respectively. Compared to OR, random-effects (RE) modeling indicated ER resulted in statistically comparable complications (RR = 0.68; P-effect = .12) and recurrence (RR = 0.84; P-effect = .35). ER was associated with significantly shorter length of stay (LOS) compared to OR (MD = −2.9 days; P-effect <.01). Conclusions The use of ER to manage SNM was associated with significantly favorable reduction in LOS compared to OR. However, with respect to other surgical outcomes and recurrence, the current literature does not indicate either ER or OR as statistically superior. Therefore, until greater validation of these associations can be proven, expectations that ER for SNMs confers superior surgical outcomes compared to OR should be tempered.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Advani, Ranjana H. , Bartlett, Nancy L. , Chang, Julie , Christian, Beth , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Khan, Nadia , Krivacic, Susan, LaCasce, Ann S. , Nademanee, Auayporn, Rabinovitch, Rachel , Reddy, Nishitha , Roberts, Kenneth B. , Smith, Stephen D. , Swinnen, Lode J., Dwyer, Mary A., Sundar, Hema, Bartlett, Nancy L , Advani, Ranjana H , Khan, Nadia , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Caimi, Paolo F. , Chavez, Julio C , Habermann, Thomas M. , Harris, Nancy L. , Kelsey, Chris R. , Mehta, Amitkumar , Reid, Erin G , Snyder, Erin Dunn , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 650-661

10.6004/jnccn.2019.0029 | PMID 31200358 Get It

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Kumar, Emil , Korfi, Koorosh , Leukam, Michael , Ansell, Stephen M. , Scott, J S, Rallis, Kathrine S , Clear, Andrew , Calaminici, Maria , Wang, J., Smith, Sonali M. , Novak, Anne J. , Bewicke‐Copley, Findlay , Witzig, Thomas E. , Scott, J., Efeyan, Alejo , Okosun, Jessica , Fitzgibbon, Jude

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 209

10.1097/01.hs9.0000560152.86937.ed Get It

Background:With an expanding array of novel treatment options in follicular lymphoma (FL), we largely lack effective biomarkers to predict response in this molecularly heterogeneous disease. Activating mutations focused on components of the nutrient‐sensing arm of the mTORC1 pathway (RRAGC, ATP6V1B2, ATP6AP1), are particularly enriched in FL, occurring in ∼30% of cases. Meanwhile, clinical mTOR inhibitors (mTORi) have shown some promise, with response rates of 50–60% in relapsed/refractory FL.Aims:We therefore sought to determine whether gene mutation status ‐ particularly in genes regulating the mTOR pathway – may represent biomarkers of mTORi‐response in FL.Methods:We retrospectively analyzed pre‐treatment tumor samples from relapsed/refractory FL patients treated on two phase II clinical trials with single agent mTOR inhibitors, everolimus (NCT00436618) or temsirolimus (NCT00290472), with well characterized clinical outcomes. In total, 21 patients had available biopsies, consisting of 15 everolimus‐ and 6 temsirolimus‐treated cases.Tumor DNA extracted from formalin fixed paraffin embedded (FFPE) tissue was subjected to targeted sequencing using a 22 gene panel comprising genes recurrently mutated in FL, and PI3K/AKT/mTOR pathway genes mutated in germinal center lymphomas. Libraries were prepared using capture‐based target enrichment (Nonacus), and sequenced on the NextSeq550 (Illumina) with a mean coverage depth of x700. A stringent bioinformatic pipeline was adopted with variants called with VarScan2, and a 10% variant allele frequency (VAF) threshold was employed to filter out sequencing artefacts due to the FFPE material. 100% (15/15) of a selection of variants were validated by Sanger sequencing. Staining for pS6 was undertaken on tissue slides to examine downstream mTOR activation by immunohistochemistry.Results:Overall response rate (CR and PR) was 48% (10/21). Mutational analysis showed no significant association between clinical response and mTORC1‐pathway mutations (mut) taken individually or collectively; although, absolute numbers of mutations in these genes were low, including RRAGC (responder: 0/10 mut vs non‐responder: 1/11 mut), ATP6AP1 (responder: 1/10 vs non‐responder: 1/11), and ATP6V1B2 (responder: 1/10 vs non‐responder 3/11). Notably, no difference in pS6 staining was seen between responders and non‐responders.However, we found mutations in the epigenetic regulator CREBBP to be enriched in the responder group (100% (10/10) responders vs 54.5% (6/11) non‐responders, p = 0.04). This effect was more pronounced when considering only mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP, with HAT mutations seen in 100% (10/10) responders, and 27.3% (3/11) non‐responders (p = 0.001).Summary/Conclusion:Mutations in the mTOR pathway did not predict for response to mTOR inhibition in our study. The enrichment of CREBBP mutations in responders, and particularly those affecting the catalytic HAT domain, points to CREBBP as a potential biomarker of response which warrants validation in trials of drugs modulating the PI3K/AKT/mTOR axis. More broadly our data may lend support to a distinct clinical and biological behavior of CREBBP HAT domain‐mutant disease that also warrants further evaluation. Taken together, our findings highlight the potential opportunities afforded by undertaking correlative studies, and underlines the need to incorporate prospective biomarker discovery into clinical trials in order to help focus future therapeutic strategies more rationally.
Long-term Outcomes Following Kidney Transplantation From Donors With Acute Kidney Injury
Heilman, Raymond L. , Kumar, Anjushree , Srinivasan, Ananth, Huskey, Janna L. , Khamash, Hasan , Mathur, Amit K. , Moss, Adyr A. , Reddy, Kunam S. , Khamash, Hasan A, Smith, Maxwell L. , Smith, Byron H. , Srinivasan, Ananth, Jadlowiec, Caroline C.

Mayo Clinic

Transplantation | June 14, 2019 | Volume: 103 | Issue: 9 | Pages: e263-e272

10.1097/tp.0000000000002792 | PMID 31205261 Get It

Background. Kidneys from deceased donors with acute kidney injury (AKI) are more likely to be discarded because of concerns for poor outcomes after transplantation. The aim of this study was to determine the long-term outcomes of a large cohort of patients transplanted utilizing kidneys from deceased donors with AKI. Methods. All patients receiving a deceased donor kidney transplant during a recent 10-year period were included. Acute Kidney Injury Network (AKIN) criteria were used to classify the donors. Donor kidneys with >10% cortical necrosis or more than mild chronic changes were discarded. The primary outcome is the combined endpoint of death or graft loss. Results. The cohort included 1313 kidneys from 974 donors, AKIN stage 0 (no AKI) in 319 (24.3%), stage 1 in 370 (28.2%), stage 2 in 177 (13.5), and stage 3 in 447 (34.0%). Estimated 5-year graft survival (95% confidence interval) was 78.5% (72.5-84.5), 77.8% (72.8-82.1), 83.8% (76.8-88.9), and 84.6% (79.5-88.7) for AKIN donor stage 0 to 3, respectively (log-rank P = 0.10). After adjusting for baseline differences, the hazard ratio (95% confidence interval) for the combined endpoint for the AKIN stage 3 group (relative to AKIN 0 group) was 0.70 (0.45-1.10). Delayed graft function occurred in 44.6% and 75.4% of AKIN 2 and 3 groups, as compared to 33.9% and 33.5% in AKIN 0 and 1 ( P < 0.001). Conclusion. We conclude that transplanting selected kidneys from deceased donors with AKI with preimplantation biopsy showing <10% cortical necrosis and no more than mild chronic changes have excellent long-term graft survival.
Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model
Guillerey, Camille , Nakamura, Kyohei , Pichler, Andrea, Barkauskas, Deborah S. , Krumeich, Sophie, Stannard, Kimberley, Miles, Kim, Harjunpää, Heidi , Yu, Yuan , Casey, Mika , Doban, Alina I. , Lazar, Mircea , Härtel, Günter , Vučković, Slavica , Bergsagel, P. Leif , Chesi, Marta , Hill, Geoffrey R. , Martinet, Ludovic , Bergsagel, P. Leif , Hill, Geoffrey R , Smith, David , Teng, Michele W.L. , Smyth, Mark J.

Mayo Clinic

JCI Insight | June 13, 2019 | Volume: 4 | Issue: 14 | Pages: No page available

10.1172/jci.insight.125932 | PMID 31194697 Get It

Immunotherapy holds promise for patients with multiple myeloma (MM), but little is known about how MM-induced immunosuppression influences response to therapy. Here, we investigated the impact of disease progression on immunotherapy efficacy in the Vk*MYC mouse model. Treatment with agonistic anti-CD137 (4-1BB) mAbs efficiently protected mice when administered early but failed to contain MM growth when delayed more than 3 weeks after Vk*MYC tumor cell challenge. The quality of the CD8 + T cell response to CD137 stimulation was not altered by the presence of MM, but CD8 + T cell numbers were profoundly reduced at the time of treatment. Our data suggest that an insufficient ratio of CD8 + T cells to MM cells (CD8/MM ratio) accounts for the loss of anti-CD137 mAb efficacy. We established serum M-protein levels prior to therapy as a predictive factor of response. Moreover, we developed an in silico model to capture the dynamic interactions between CD8 + T cells and MM cells. Finally, we explored two methods to improve the CD8/MM ratio: anti-CD137 mAb immunotherapy combined with Treg depletion or administered after chemotherapy treatment with cyclophosphamide or melphalan efficiently reduced MM burden and prolonged survival. Together, our data indicate that consolidation treatment with anti-CD137 mAbs might prevent MM relapse.
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Zhu, Jun , Smith, Stephen D. , O’Connor, Owen A. , Luo, Wen‐Lin, Shazer, Ronald , Zhang, L., Han, Isabel, Jivani, Manoj A., Liu, Y. , Nowakowski, Grzegorz S. , Song, Yuqin

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 70-70

10.1002/hon.37_2629 Get It

Murine T Cell Maturation Entails Protection from MBL2, but Complement Proteins Do Not Drive Clearance of Cells That Fail Maturation in the Absence of NKAP
Dash, Barsha, Belmonte, Paul , Fine, Sydney R. , Shapiro, Michael J. , Chung, Ji Young, Schwab, Aaron , McCue, Shaylene , Rajcula, Matthew, Shapiro, Virginia Smith , Belmonte, Paul J , Schwab, Aaron D, Shapiro, Virginia S , Schwab, Aaron D , Shapiro, Michael Jeremy

Mayo Clinic

The Journal of Immunology | June 7, 2019 | Volume: 203 | Issue: 2 | Pages: 408-417

10.4049/jimmunol.1801443 | PMID 31175160 Get It

Abstract Recent thymic emigrants that fail postpositive selection maturation are targeted by complement proteins. T cells likely acquire complement resistance during maturation in the thymus, a complement-privileged organ. To test this, thymocytes and fresh serum were separately obtained and incubated together in vitro to assess complement deposition. Complement binding decreased with development and maturation. Complement binding decreased from the double-positive thymocyte to the single-positive stage, and within single-positive thymocytes, complement binding gradually decreased with increasing intrathymic maturation. Binding of the central complement protein C3 to wild-type immature thymocytes required the lectin but not the classical pathway. Specifically, MBL2 but not MBL1 was required, demonstrating a unique function for MBL2. Previous studies demonstrated that the loss of NKAP, a transcriptional regulator of T cell maturation, caused peripheral T cell lymphopenia and enhanced complement susceptibility. To determine whether complement causes NKAP-deficient T cell disappearance, both the lectin and classical pathways were genetically ablated. This blocked C3 deposition on NKAP-deficient T cells but failed to restore normal cellularity, indicating that complement contributes to clearance but is not the primary cause of peripheral T cell lymphopenia. Rather, the accumulation of lipid peroxides in NKAP-deficient T cells was observed. Lipid peroxidation is a salient feature of ferroptosis, an iron-dependent nonapoptotic cell death. Thus, wild-type thymocytes naturally acquire the ability to protect themselves from complement targeting by MBL2 with maturation. However, NKAP-deficient immature peripheral T cells remain scarce in complement-deficient mice likely due to ferroptosis.
Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.
Butler, Nicole , White, Carol , Smith, Mary Lou , Mangat, Pam K. , Kurian, Allison W. , Railey, Elda , Hawley, Sarah T. , Schilsky, Richard L. , Kurian, Allison W , Bruinooge, Suanna S. , Dueck, Amylou C. , Gray, Stacy W.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 6531-6531

10.1200/jco.2019.37.15_suppl.6531 Get It

6531 Background: This survey of Targeted Agent and Profiling Utilization Registry (TAPUR) Study physicians examined use, attitudes, and perception of tumor genomic testing (TGT), defined as any DNA test performed on tumor specimen/plasma. TAPUR is a multibasket study of marketed agents targeting tumor genomics. Methods: 333 physicians at 54 TAPUR sites were surveyed (2016-2017). Survey domains included use of TGT, barriers to ordering TGT, and genomic confidence. Surveys included 3 scenarios for TGT ordering 1) pretreated advanced cancer patients (pts) without options, 2) newly diagnosed, untreated, metastatic pts and 3) early stage/potentially curable pts with standard options. Data were analyzed with descriptive statistics. Results: 112 physicians responded (33%). The table displays demographics and genomic confidence. Respondents reported a median of 25% of their pts had TGT in past 12 months for trials/routine care (range 0-85%). Barriers to testing included access to tumor specimen (86%), insurance coverage (67%), concerns that results will not be actionable (55%), and test issues (wait time, unsure which test/lab to use, test accuracy) (54%). TGT was ordered most often for scenario 1 (96%) and 2 pts (70%). Few respondents (32%) would order testing in scenario 3. Of those who reported testing for scenarios 1 & 2, most told pts that results could inform treatment/prognosis/trials (97%) or may be uninformative (84%). In all scenarios, pt expectations of TGT results were discussed prior to testing. A minority reported frequently telling pts in advance that results could inform heritable cancer susceptibility (37%). Conclusions: Confidence in using TGT was high. TGT was performed most for pts with advanced cancer and few options. Availability of specimens was largest barrier reported, indicating the importance of blood-based tests. Few respondents discussed implications of germline findings in advance, despite growing evidence of germline findings in somatic testing. [Table: see text]
EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity.
Marcath, Lauren A. , Vangipuram, Kiran, Gersch, Christina L. , Burness, Monika L. , Griggs, Jennifer J. , Poznak, Catherine Van , Hayes, Daniel F. , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Kidwell, Kelley M. , Lavoie Smith, Ellen M , Henry, N. Lynn

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 532-532

10.1200/jco.2019.37.15_suppl.532 Get It

532 Background: Chemotherapy induced peripheral neuropathy (CIPN) is a common, debilitating paclitaxel side effect that has been primarily attributed to cumulative systemic paclitaxel exposure. Paclitaxel dose-adjustment to achieve target systemic exposure decreases but does not eliminate severe CIPN, suggesting some patients are inherently CIPN-sensitive. Ephrin ( EPHA) polymorphisms have been reported to increase CIPN occurrence (Baldwin 2012, Leandro-Garcia 2013, Boora 2016) but replication has been challenging, perhaps due to the inability to isolate CIPN-sensitivity by accounting for systemic exposure differences. The study purpose was to determine if EPHA genetic variants previously associated with CIPN occurrence are associated with CIPN-sensitivity. Methods: PN was assessed at baseline and weekly using the 8-item sensory subscale (CIPN8) of the patient-reported EORTC CIPN20 in patients receiving paclitaxel 80 mg/m2 weekly x 12. EPHA4, EPHA5, EPHA6, and EPHA8 were sequenced in germline DNA. Associations with higher PN-sensitivity were tested for three genetic models (total variants, coding variants, and rs7349683) by incorporating genetics into previously published CIPN8 predictive models that included measured paclitaxel exposure. Significant associations were tested for association with higher risk of PN-related treatment disruption (i.e. dose decrease, delay, or discontinuation). Results: In the 59 included patients, carrying EPHA5 rs7349683 was associated with greater CIPN sensitivity (beta coefficient: 0.40, standard error: 0.14, p = 0.005), indicating these patients had a greater increase in CIPN8 during treatment than would be predicted based on cumulative paclitaxel exposure. Rs7349683 was not associated with increased PN-induced treatment disruption, perhaps due to the low number of events (n = 19). Conclusions: Using a novel approach that isolates CIPN-sensitivity by accounting for measured paclitaxel exposure, our results provide further evidence that EPHA5 rs7349683 may be a promising marker for CIPN. If additional validation studies confirm this association, genetic testing could enable personalized treatment strategies to prevent CIPN in patients with breast cancer.
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer
Fischer‐Valuck, Benjamin W. , Michalski, Jeff M. , Christodouleas, John P. , DeWees, T.A. , Kim, Eric H. , Smith, Zachary L. , Andriole, Gerald L. , Arora, Vivek , Bullock, Arnold, Carmona, Ruben, Figenshau, Robert S., Grubb, Robert L. , Guzzo, Thomas J., Knoche, E, Malkowicz, S. Bruce, Mamtani, Ronac , Pachynski, Russell K. , Roth, Bruce J. , Zaghloul, Mohamed S. , Baumann, Brian C. , DeWees, Todd A, Mamtani, Ronac , Baumann, Brian C , DeWees, Todd A , Pachynski, Russell K , Mitra, Nandita , Knoche, Eric M., Gay, Hiram A.

Mayo Clinic

Cancer Medicine | May 23, 2019 | Volume: 8 | Issue: 8 | Pages: 3698-3709

10.1002/cam4.2102 | PMID 31119885 Get It

AbstractBackgroundLocal‐regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can reduce LF and may enhance overall survival (OS) but has no defined role. We hypothesized that the addition of PORT would improve OS in LABC in a large nationwide oncology database.MethodsWe identified ≥ pT3pN0‐3M0 LABC patients in the National Cancer Database diagnosed 2004‐2014 who underwent RC ± PORT. OS was calculated using Kaplan‐Meier and Cox proportional hazards regression modeling was used to identify predictors of OS. Propensity matching was performed to match RC patients who received PORT vs those who did not.Results15,124 RC patients were identified with 512 (3.3%) receiving PORT. Median OS was 20.0 months (95% CI, 18.2‐21.8) for PORT vs 20.8 months (95% CI, 20.3‐21.3) for no PORT (P = 0.178). In multivariable analysis, PORT was independently associated with improved OS: hazard ratio 0.87 (95% CI, 0.78‐0.97); P = 0.008. A one‐to‐three propensity match yielded 1,858 patients (24.9% receiving PORT and 75.1% without). In the propensity‐matched cohort, median OS was 19.8 months (95% CI, 18.0‐21.6) for PORT vs 16.9 months (95% CI, 15.6‐18.1) for no PORT (P = 0.030). In the propensity‐matched cohort of urothelial carcinoma patients (N = 1,460), PORT was associated with improved OS for pT4, pN+, and positive margins (P < 0.01 all).ConclusionIn this observational cohort, PORT was associated with improved OS in LABC. While the data should be interpreted cautiously, these results lend support to the use of PORT in selected patients with LABC, regardless of histology. Prospective trials of PORT are warranted.